Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys 10,14]N/OFQ(1-14)NH2

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 368, Issue 6, 2003, Pages 528-537

  Kitayama, M ^a   Barnes, T A ^a   Carra, G ^b   McDonald, J ^a   Calo, G ^b   Guerrini, R ^b   Rowbotham, D J ^a   Smith, G ^a   Lambert, D G ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

cAMP formation; Cyclic N OFQ peptides; Electrically stimulated vas deferens; GTP 35S binding; N OFQ receptor; Nociceptin orphanin FQ (N OFQ); Radioligand binding

Indexed keywords

CALCIUM CHANNEL; CYCLIC AMP; DIPRENORPHINE; FORSKOLIN; NALOXONE; NOCICEPTIN; RADIOLIGAND; TRITIUM;

ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BRAIN CORTEX; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIZATION; DRUG STRUCTURE; ELECTROSTIMULATION; INCUBATION TIME; MALE; NONHUMAN; POTASSIUM CONDUCTANCE; RAT; RECEPTOR BINDING; VAS DEFERENS;

ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; CEREBRAL CORTEX; CHO CELLS; CRICETINAE; CYCLIC AMP; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; FEMALE; FORSKOLIN; GTP-BINDING PROTEINS; MALE; MICE; MUSCLE CONTRACTION; NALOXONE; OPIOID PEPTIDES; PHENYLALANINE; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECOMBINANT PROTEINS; VAS DEFERENS;

EID: 0347991783     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-003-0821-5     Document Type: Article

References (34)

1. Albrecht E, Samovilova NN, Oswald S, Baeger I, Berger H (1998) Nociceptin (orphanin FQ): high-affinity and high-capacity binding site coupled to low-potency stimulation of guanylyl-5γ-O-(gamma-thio)-triphosphate binding in rat brain membranes. J Pharmacol Exp Ther 286:896-902
2. Ambo A, Hamazaki N, Yamada Y, Nakata E, Sasaki Y (2001) Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides. J Med Chem 44: 4015-4018
3. Annis I, Hargittai B, Barany G (1997) Disulfide bond formation in peptides. Methods Enzymol 289:198-221
4. Bigoni R, Giuliani S, Calo G, Rizzi A, Guerrini R, Salvadori S, Regoli D, Maggi CA (1999) Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn-Schmiedebergs Arch Pharmacol 359:160-167
5. Bigoni R, Cao G, Rizzi A, Okawa H, Regoli D, Smart D, Lambert DG (2002) Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors. Can J Physiol Pharmacol 80:407-412
6. Calo G, Rizzi A, Bogoni G, Neugebauer V, Salvadori S, Guerrini R, Bianchi C, Regoli D (1996) The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur J Pharmacol 311:R3-R5
7. Calo G, Bigoni R, Rizzi A, Guerrini R, Salvadori S, Regoli D (2000a) Nociceptin/orphanin FQ receptor ligands. Peptides 21: 935-947
8. 2, a new selective nociceptin receptor antagonist. Br J Pharmacol 129:1183-1193
9. Calo G, Guerrini R, Rizzi A, Salvadori S, Regoli D (2000c) Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol 129:1261-1283
10. 2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 136:303-311
11. Dooley CT, Houghten RA (2000) Orphanin FQ/nociceptin receptor binding studies. Peptides 21:949-960
12. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-77
13. Guerrini R, Calo G, Rizzi A, Bianchi C, Lazarus LH, Salvadori S, Temussi PA, Regoli D (1997) Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem 40:1789-1793
14. Guerrini R, Calo G, Rizzi A, Bigoni R, Rizzi D, Regoli D, Salvadori S (2000) Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A. Peptides 21:923-933
15. Hashiba E, Harrison C, Calo G, Guerrini R, Rowbotham DJ, Smith G, Lambert DG (2001) Characterisation and comparison of novel ligands for the nociceptin/orphanin FQ receptor. Naunyn-Schmiedebergs Arch Pharmacol 363:28-33
16. Hashiba E, Lambert DG, Farkas J, Toth G, Smith G (2002a) Comparison of the binding of [(3)H]nociceptin/orphaninFQ(1-13) NH(2), [(3)H]nociceptin/ orphaninFQ(1-17)OH and [(125)1] Tyr(14)nociceptin/orphaninFQ(1-17)OH to recombinant human and native rat cerebrocortical nociceptin/orphanin FQ receptors. Neurosci Lett 328:5-8
17. Hashiba E, Lambert DG, Jenck F, Wichmann J, Smith G (2002b) Characterisation of the non-peptide nociceptin receptor agonist, Ro64-6198 in Chinese hamster ovary cells expressing recombinant human nociceptin receptors. Life Sci 70:1719-1725
18. Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379
19. Knoflach F, Reinscheid RK, Civelli O, Kemp JA (1996) Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. J Neurosci 16:6657-6664
20. Kramer TH, Toth G, Haaseth RC, Matsunaga TO, Davis P, Hruby VJ, Burks TF (1991) Influence of peptidase inhibitors on the apparent agonist potency of delta selective opioid peptides in vitro. Life Sci 48:881-886
21. McDonald J, Barnes TA, Calo G, Guerrini R, Rowbotham DJ, Lambert DG (2002) Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma35S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor. Eur J Pharmacol 443:7-12
22. McDonald J, Calo G, Guerrini R, Lambert DG (2003a) UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies. Naunyn-Schmiedebergs Arch Pharmacol 367:183-187
23. McDonald J, Barnes TA, Okawa H, Williams J, Calo G, Rowbotham DJ, Lambert DG (2003b) Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression. Studies using the ecdysone inducible mammalian expression system. Br J Pharmacol 140:61-70
24. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B et al (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532-535
25. Mogil JS, Pasternak GW (2001) The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 53:381-415
26. Okada K, Sujaku T, Chuman Y, Nakashima R, Nose T, Costa T, Yamada Y, Yokoyama M, Nagahisa A, Shimohigashi Y (2000) Highly potent nociceptin analog containing the Arg-Lys triple repeat. Biochem Biophys Res Commun 278:493-498
27. Okawa H, Hirst RA, Smart D, McKnight AT, Lambert DG (1998) Rat central ORL-1 receptor uncouples from adenylyl cyclase during membrane preparation. Neurosci Lett 246:49-52
28. Okawa H, Nicol B, Bigoni R, Hirst RA, Calo G, Guerrini R, Rowbotham DJ, Smart D, McKnight AT, Lambert DG (1999) Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors. Br J Pharmacol 127: 123-130
29. Paterlini G, Portoghese PS, Ferguson DM (1997) Molecular simulation of dynorphin A-(1-10) binding to extracellular loop 2 of the kappa-opioid receptor. A model for receptor activation. J Med Chem 40:3254-3262
30. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma Jr FJ, Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 270:792-794
31. Terenius L, Sandin J, Sakurada T (2000) Nociceptin/orphanin FQ metabolism and bioactive metabolites. Peptides 21:919-922
32. Topham CM, Mouledous L, Poda G, Maigret B, Meunier JC (1998) Molecular modelling of the ORL1 receptor and its complex with nociceptin. Protein Eng 11:1163-1179
33. Vaughan CW, Christie MJ (1996) Increase by the ORL1 receptor (opioid receptor-like1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurones. Br J Pharmacol 117:1609-1611
34. Zhang C, Miller W, Valenzano KJ, Kyle DJ (2002) Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem 45:5280-5286